FFO
VERV

Fortitude Family Office’s Verve Therapeutics VERV Stock Holding History

Fortitude Family Office’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-87
Closed -$977 – 2145
2025
Q2 		$977 Buy
+87
New +$496 ﹤0.01% 1522

Other funds holding VERV

GCM
Greenland Capital Management New York $787M AUM 40.68% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Fortitude Family Office's VERV Position: Q3 2025 in Review

Fortitude Family Office sold out of Verve Therapeutics (VERV) in Q3 2025, closing a stake of 87 shares — an estimated $977 sold.

Fortitude Family Office first reported a position in VERV in Q2 2025 and held it in 1 quarter. The position peaked at $977 in Q2 2025. 6 funds tracked by Wall St. Rank hold VERV as of Q3 2025.

  • Fortitude Family Office reported no remaining Verve Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Fortitude Family Office sold 87 Verve Therapeutics shares in Q3 2025, an estimated $977.
  • Fortitude Family Office first reported a position in Verve Therapeutics in Q2 2025 and held it in 1 quarter.
  • Fortitude Family Office's Verve Therapeutics position peaked at $977 in Q2 2025.
  • 6 funds tracked by Wall St. Rank held Verve Therapeutics as of Q3 2025.

Based on Fortitude Family Office's 13F filing for Q3 2025, filed 17 Oct 2025.